Influence of diagnostic and therapeutic doses on thyroid remnant ablation rates

Radioiodine ablation of thyroid tissue after subtotal thyroidectomy has been shown to decrease recurrence in certain subsets of patients with well-differentiated thyroid cancer. In a substantial percentage of cases (20-30%), initial ablation of the thyroid remnant fails, necessitating a second treatment. The factors associated with ablation failure are not fully understood. In particular, it is not certain whether the use of doses higher than 3.70 GBq would result in any additional benefit, or whether there is a ‘stunning’ effect of the diagnostic dose of 131I on the subsequent ablation rate. A retrospective analysis was performed of all patients (n = 389) with well-differentiated thyroid cancer treated at our institution between 1992 and 2001. Remnant ablation success was determined by a whole-body radioiodine scan. The following factors, thought to be associated with thyroid remnant ablation, were studied by logistic regression analysis: age, gender, tumour histology, stage, pre-therapy neck uptake of 131I, diagnostic dose, ablation dose, time between diagnostic and therapeutic dose (T1), time between therapeutic administration and the first follow-up whole-body scan (T2) and the thyroid-stimulating hormone (TSH) level measured at the time of therapy. Follow-up whole-body scans were available in 214 patients. We found no association with age, gender, histology, TSH level, neck uptake, diagnostic dose and successful ablation. The therapeutic dose was the only variable found to be associated with success (odds ratio, 1.96 per 1.85 GBq increment; 95% confidence interval, 1.11-3.46). Our results confirm the presence of a significant percentage of ablation failures (24.4%) despite the use of high ablative doses (3.70-7.40 GBq). Higher therapeutic doses are associated with higher rates of successful ablation, even when administered to patients with more advanced stages. Using our protocol, higher diagnostic doses were not associated with higher rates of ablation failure.

[1]  H. Creutzig High or low dose radioiodine ablation of thyroid remnants? , 2004, European Journal of Nuclear Medicine.

[2]  Eva Forssell-Aronsson,et al.  Stunning of iodide transport by (131)I irradiation in cultured thyroid epithelial cells. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[3]  W. Brenner Is thyroid stunning a real phenomenon or just fiction? , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[4]  M. Dempsey,et al.  Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic 131I and 123I , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[5]  S. Ilgan,et al.  Post-surgical ablation of thyroid remnants with high-dose 131I in patients with differentiated thyroid carcinoma , 2001, Nuclear medicine communications.

[6]  G. Braunstein,et al.  The nonimpact of thyroid stunning: remnant ablation rates in 131I-scanned and nonscanned individuals. , 2001, The Journal of clinical endocrinology and metabolism.

[7]  S. Naddaf,et al.  Neck and whole-body scanning with 5-mCi dose of (123)I as diagnostic tracer in patients with well-differentiated thyroid cancer. , 2001, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[8]  A. Alavi,et al.  Superiority of Iodine-123 Compared with Iodine-131 Scanning for Thyroid Remnants in Patients with Differentiated Thyroid Cancer , 2001, Clinical nuclear medicine.

[9]  M. Bajén,et al.  Effect of a diagnostic dose of 185 MBq 131I on postsurgical thyroid remnants. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[10]  J. Hurley,et al.  Management of thyroid cancer: radioiodine ablation, "stunning," and treatment of thyroglobulin-positive, (131)I scan-negative patients. , 2000, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[11]  R. O'mara,et al.  Absence of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  B. de Keizer,et al.  Fixed dosage of 131I for remnant ablation in patients with differentiated thyroid carcinoma without pre-ablative diagnostic 131I scintigraphy , 2000, Nuclear medicine communications.

[13]  S. Doi,et al.  Ablation of the thyroid remnant and 131I dose in differentiated thyroid cancer , 2000, Clinical endocrinology.

[14]  J. Humm,et al.  Radioiodine uptake in thyroid remnants during therapy after tracer dosimetry. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[15]  S. Bae,et al.  Comparison of Diagnostic and Post-therapy Radioiodine Scan in Well-Differentiated Thyroid Cancer and the Clinical Outcome , 2000 .

[16]  K. Spicer,et al.  The usefulness of iodine-123 whole-body scans in evaluating thyroid carcinoma and metastases. , 1999, Journal of nuclear medicine technology.

[17]  E. Mazzaferri An overview of the management of papillary and follicular thyroid carcinoma. , 1999, Thyroid : official journal of the American Thyroid Association.

[18]  L. Wartofsky Management of Patients with Scan Negative, Thyroglobulin Positive Differentiated Thyroid Carcinoma , 1998 .

[19]  J. Muratet,et al.  Influence of scanning doses of iodine-131 on subsequent first ablative treatment outcome in patients operated on for differentiated thyroid carcinoma. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  R. Tsang,et al.  Prescribing 131Iodine based on neck uptake produces effective thyroid ablation and reduced hospital stay. , 1998, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[21]  P. Kao,et al.  The effects of radioactive iodine in thyroid remnant ablation and treatment of well differentiated thyroid carcinoma. , 1998, The British journal of radiology.

[22]  J. Clerc,et al.  Decreased uptake of therapeutic doses of iodine-131 after 185-MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma , 1998, European Journal of Nuclear Medicine.

[23]  J. D. Lin,et al.  Use of radioactive iodine for thyroid remnant ablation in well-differentiated thyroid carcinoma to replace thyroid reoperation. , 1998, American journal of clinical oncology.

[24]  M. Schlumberger,et al.  THERAPEUTIC CONTROVERSY The Use of Radioactive Iodine in Patients with Papillary and Follicular Thyroid Cancer , 1998 .

[25]  P. Giraud,et al.  Predicting the efficacy of first iodine-131 treatment in differentiated thyroid carcinoma. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[26]  I. Mcdougall,et al.  74 MBq radioiodine 131I does not prevent uptake of therapeutic doses of 131I (i.e. it does not cause stunning) in differentiated thyroid cancer. , 1997, Nuclear medicine communications.

[27]  C. Bal,et al.  Prospective randomized clinical trial to evaluate the optimal dose of 131I for remnant ablation in patients with differentiated thyroid carcinoma , 1996, Cancer.

[28]  I. Mcdougall,et al.  What is the role of 1100 MBq (< 30 mCi) radioiodine 131I in the treatment of patients with differentiated thyroid cancer? , 1996, Nuclear medicine communications.

[29]  C. Bal,et al.  Prospective randomized clinical trial to evaluate the optimal dose of 131 I for remnant ablation in patients with differentiated thyroid carcinoma. , 1996, Cancer.

[30]  A. Samuel,et al.  Radioiodine therapy for well-differentiated thyroid cancer: a quantitative dosimetric evaluation for remnant thyroid ablation after surgery. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[31]  R. Tsang,et al.  Radioiodine ablation of residual tissue in thyroid cancer: relationship between administered activity, neck uptake and outcome. , 1994, The British journal of radiology.

[32]  N. Katoh,et al.  Iodine-131 treatment of thyroid cancer: relation between effective half-life and efficacy of treatment. , 1994, Radiation medicine.

[33]  E. S. Pedro,et al.  Influence of various scanning doses on subsequent I-131 ablation of thyroid remnants , 1994 .

[34]  H. Park,et al.  Influence of diagnostic radioiodines on the uptake of ablative dose of iodine-131. , 1994, Thyroid : official journal of the American Thyroid Association.

[35]  Chen Wl,et al.  Radioiodine I-131 therapy in the management of differentiated thyroid carcinoma: a review of 202 patients. , 1993 .

[36]  W. Huang,et al.  Radioiodine I-131 therapy in the management of differentiated thyroid carcinoma: a review of 202 patients. , 1993, Journal of the Formosan Medical Association = Taiwan yi zhi.

[37]  K. Johansen,et al.  Comparison of 1073 MBq and 3700 MBq iodine-131 in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid cancer. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[38]  M. Schlumberger,et al.  Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest X-rays. , 1988, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[39]  L. Woolner,et al.  Papillary thyroid cancer treated at the Mayo Clinic, 1946 through 1970: initial manifestations, pathologic findings, therapy, and outcome. , 1986, Mayo Clinic proceedings.

[40]  R. Lloyd,et al.  An analysis of "ablation of thyroid remnants" with I-131 in 511 patients from 1947-1984: experience at University of Michigan. , 1984, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[41]  H. Blattmann,et al.  [Effectiveness of high-dosage radioiodine therapy in the elimination of remnant tissue following total thyroidectomy]. , 1984, Nuklearmedizin. Nuclear medicine.

[42]  G. Guiraudon,et al.  Pulmonary metastases in differentiated thyroid carcinoma. Study of 58 cases with implications for the primary tumor treatment , 1984, Cancer.

[43]  C. Kuni,et al.  Failure of low doses of 131I to ablate residual thyroid tissue following surgery for thyroid cancer. , 1980, Radiology.

[44]  W. Blahd,et al.  Radioiodine I‐131 therapy in the management of thyroid cancer. A prospective study , 1977 .